Metastatic prostate cancer cases increased as screening use declined
https://www.facingourrisk.org/XRAY/metastatic-prostate-cancer-increased
Full article: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790041?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jamanetworkopen.2022.2246
The number of people diagnosed with metastatic prostate cancer increased following a change in recommendations around the use of routine prostate cancer screening. (posted 6/13/22)
Este artículo está disponible en español.
Open Clinical Trials
The following are studies looking at ways to screen for prostate cancer in people at high risk:
- NCT05129605: Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS). This study investigates how enhanced prostate cancer screening using MRI improves early detection rates and provides further understanding of how inherited mutations can lead to the development of prostate cancer.
- NCT03805919: Men at High Genetic Risk for Prostate Cancer. This study use MRI to screen for prostate cancer in high-risk men. This study is open to men with an inherited mutation in BRCA1, BRCA2, HOX B13, ATM, NBN, TP53, MLH1, MSH2, MSH6, PMS2, EPCAM, CHECK2, PALB2, RAD51D, BRIP1 or FANCA.
- NCT04472338: Prostate Screening for Men With Inherited Risk of Developing Aggressive Prostate Cancer, PATROL Study. This study looks at ways to detect prostate cancer earlier in men who are at increased genetic risk of developing prostate cancer that forms, grows, or spreads quickly (aggressive). The study is open to men with mutations associated with prostate cancer risk.
-
NCT05608694: MRI Screening in Men at High Risk of Developing Prostate Cancer. This study determines whether or not Magnetic Resonance Images (MRIs) identify high-grade cancers earlier and more frequently in men at high risk of developing prostate cancer.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.